DannyHiroshiSugimotoMDCPI

Internal Medicine • Chicago, IL

Medical Director. Preventative Cardiology

Join to view full profile

Dr. Sugimoto is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sugimoto's full profile

Already have an account?

Office
800 S Wells St
Ste M15
Chicago, IL 60607
Phone+1 312-431-6765

Fax+1 312-431-7959

Education & Training

Rush University Medical CenterResidency, Internal Medicine, 1983 - 1986
Rush Medical College of Rush University Medical CenterClass of 1983

Certifications & Licensure

IL State Medical License 1985 - 2026
American Board of Internal Medicine Internal Medicine

Clinical Trials

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2014 Apr 01
Terminated
Phase 2
A Study of LY2623091 in Participants With High Blood Pressure Start of enrollment: 2014 Aug 01
Completed
Phase 2
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
Completed
Phase 2
Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL Start of enrollment: 2017 Apr 06
Suspended
Phase 2
Join now to see all

Publications & Presentations

PubMed

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity.
Ute Klinkardt, Mirjam Schunk, John Ervin, Christoph Schindler, Danny Sugimoto
Human Vaccines & Immunotherapeutics. 2024-12-31
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 di...
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari
Diabetes, Obesity & Metabolism. 2024-06-01
3 citations
Cardiometabolic risk factors efficacy of semaglutide in the STEP program.
Anastassia Amaro, Neil S Skolnik, Danny Sugimoto
Postgraduate Medicine. 2022-01-01

Journal Articles

Efficacy of iGlarLixi, a Fixed‐Ratio Combination of Insulin Glargine and Lixisenatide, in Patients with Type 2 Diabetes Stratified as High and Low Risk According to HE...
Danny Sugimoto, MD, Diabetes, Obesity and Metabolism